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Background/aim: β-Lactamase-producing Escherichia coli strain JJ1886 is an epidemic clone with high virulence properties. Because
this strain can survive in the bloodstream, we aimed here to understand how β-lactam antibiotics and human serum affect the growth
and gene expression of this bacterium.
Materials and methods: We report the time-dependent growth effect of normal human serum and heat-inactivated serum, together
with β-lactam antibiotics (including cefotaxime, ceftazidime, and carbenicillin), for E. coli strain JJ1886. Relative gene expression of
β-lactamase-related genes (encoding the β-lactamase regulator, CTX-M-15, and peptidoglycan glycosyltransferase) and serum survivalassociated genes (encoding lipoprotein NlpI, murein lipoprotein, lipopolysaccharide core heptose (I) kinase, lipopolysaccharide
biosynthesis protein, capsule synthesis protein, and phosphate transport system) were investigated by RT-qPCR.
Results: Cells proliferated during the exponential growth phase when the bacterium was treated with human serum. However,
cefotaxime and ceftazidime together with serum had a bactericidal effect at each of the tested time points. Downregulation was observed
in gene-encoding lipoprotein NlpI as a result of treatment with carbenicillin.
Conclusion: Serum plus cefotaxime or ceftazidime had bactericidal activities. When the bacterium was treated with human serum and
β-lactam antibiotics, there were no significant changes in relative gene expression, except for the nlpI gene.
Key words: Escherichia coli JJ1886, β-lactamase, serum, RT-qPCR, cefotaxime, ceftazidime, carbenicillin

1. Introduction
β-Lactam antibiotics are the most commonly used
broad-spectrum antibiotics in the treatment of bacterial
infections (1,2). β-Lactams interact with penicillin-binding
proteins (PBPs), which have a role in the cross-linking of
the peptidoglycan component of the bacterial cell wall.
β-Lactams inhibit transpeptidation activity of PBSs,
leading to bacterial cell lysis (3). β-Lactams with such an
effect include penicillins, cephalosporins, carbapenems,
and monobactams (2). Cefotaxime (CTX) and ceftazidime
(CAZ) are third-generation cephalosporins typically
used in the treatment of bacterial infections caused by
gram-positive bacteria, but which may also be used
against gram-negative bacteria (https://www.fda.gov/).
Similarly, carbenicillin (CAR), which belongs to the
carboxypenicillin subgroup of the penicillins, has the same
mode of action as CTX and CAZ (https://www.drugbank.
ca/drugs/DB00578; http://antibiotics.toku-e.com/).
When β-lactams are used in the treatment of bacterial
infections, the bacteria protect themselves by producing

β-lactamase enzymes. These bacteria produce β-lactamases
that hydrolyze β-lactam antibiotics (3). β-Lactamase
production occurs in bacteria when antibiotic-associated
damage to the cell wall occurs (4). CXT-M-type extendedspectrum β-lactamase (ESBL) enzymes are the most
commonly observed β-lactamases and are disseminated
rapidly among Enterobacteriaceae members, including
Escherichia coli strains (5,6). CTX-M-15 and CTX-M-14
are the most common variants of the CTX-M-type
ESBLs; CTX-M-15 has catalytic activity against CAZ (6).
Dissemination of CTX-M-15 among Enterobacteriaceae
and non-Enterobacteriaceae members, including E. coli
and Acinetobacter baumannii, is provided by transferable
plasmids (7,8). However, multiple studies have reported
that genes encoding CTX-M-15 have integrated into the
bacterial chromosome (9,10).
Few studies have addressed the expression of genes
encoding the CTX-M-15-type β-lactamase. However,
it has been reported that expression of blaCTX-M can be
changed according to the CTX concentration, growth
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phase of E. coli, and genetic location of the blaCTX-M gene
(11). Similarly, upregulation of the blaCTX-M-15 gene has
been reported in Shigella sonneii in the presence of CAZ
(12). Therefore, it can be inferred that genes encoding
CTX-M-type β-lactamases can be upregulated or
downregulated in the presence of β-lactam antibiotics.
Moreover, the control of β-lactamase gene expression is
regulated by a histidine kinase/response regulator pair
in Vibrio parahaemolyticus (4). In addition, AmpE is a
putative signaling protein in β-lactamase regulation in E.
coli, and AmpE might help reveal the effect of β-lactam on
peptidoglycan biosynthesis (13).
Rapid dissemination of CTX-M-15-type ESBLs has
led to the emergence of highly pathogenic pandemic
bacterial clones, including the CTX-M-15-producing
E. coli O25b:H4-ST131 (14,15). E. coli O25b:H4-ST131
causes bloodstream infections, including urinary
tract infection, pyelonephritis, and sepsis outside the
intestinal tract (16,17). Moreover, this strain is resistant to
extended-spectrum cephalosporin and fluoroquinolones
(18). Because E. coli O25b:H4-ST131 is multidrugresistant and carries potential virulence determinants,
it is considered an emerging pandemic clone of global
importance (19). According to phylogenetic analyses,
CTX-M-15-producing E. coli O25b:H4-ST131 has been
defined as an H30-Rx subclone. For instance, E. coli strain
JJ1886, a highly virulent CTX-M-15-producing H30-Rx
subclone of E. coli O25b:H4-ST131, was reported from a
urosepsis patient in the United States (16,20).
On the occasions that the CTX-M-15-type
β-lactamase-producing E. coli ST131 pandemic strain
has been found in the blood causing septicemia and
bacteremia, it has been resistant to the bactericidal effects
of serum (21). Many virulence factors are involved in E.
coli resistance to the bactericidal activity of serum. To
illustrate, the proteins associated with lipopolysaccharide
(LPS) biosynthesis and the K capsule have significant
contributions to serum survival, as does the outer
membrane protein (OmpA) (21,22). Moreover, serum
survival factors, including Trat, Iss, and phage proteins
encoded by plasmids, are serum survival factors in E.
coli (23). Other factors or proteins that may be involved
in serum resistance have been reported, including NlpI
lipoprotein, murein lipoprotein (Lpp), and the phosphate
transport system (24–26).
Given that the E. coli ST131 strain exhibits resistance
to many antibiotics and serum, it is important to study
the inhibitory and bactericidal effect of antibiotics and
serum on this strain. Here we investigate the effect of
β-lactam antibiotics plus human serum on E. coli strain
JJ1886 (025b:H4-ST131) growth and the gene expression
of β-lactamase and serum resistance-associated genes.

2. Materials and methods
2.1. Bacterial strains and normal human serum
The CTX-M-15-type β-lactamase-producing E. coli
epidemic strain JJ1886 was used as the test microorganism.
E. coli strain JJ1886 was kindly provided by Professor James
R Johnson (University of Minnesota, VA Medical Center,
Minneapolis, MN, USA). E. coli ATCC 25922 strain was
used as a quality control strain for minimum inhibitory
concentration (MIC) testing analysis. Normal human
serum (NHS) was commercially purchased (Panbiotech,
Germany). To inactivate the complement system of NHS,
serum was incubated at 56 °C for 30 min, resulting in heatinactivated serum (HIS) (27). NHS and HIS were stored at
–80 °C until further analysis.
2.2. Dimethyl sulfoxide stocks of bacterial strains
Dimethyl sulfoxide (DMSO) stocks of E. coli strain JJ1886
and E. coli ATCC 25922 were prepared as follows: bacterial
cultures were incubated overnight, diluted to 1/100 in
Luria Bertani (LB) broth, and grown until the logarithmic
growth phase at 37 °C (OD600: 0.8). Next, DMSO was
added to the bacterial culture, giving a final concentration
of 8%. Bacterial cultures were dispensed in volumes of 120
µL and stored at –80 °C (28).
2.3. Nitrocefin test
Nitrocefin is a chromogenic cephalosporin. Through the
procedure provided by the manufacturer (Bioanalyse),
we phenotypically tested whether E. coli strain JJ1886 is
a β-lactamase producer. E. coli ATCC 25922 was used
as a quality control strain. Nitrocefin disks change from
yellow to red within 5 min (as quickly as 15 s) when the
β-lactam antibiotic is hydrolyzed by bacterial induction of
the β-lactamase enzyme.
2.4. Determination of minimum inhibitory concentration
Carbenicillin (250 mg, Sigma), cefotaxime (100 mg,
Sigma), and ceftazidime (50 mg, Sigma) were used for the
MIC testing. MIC analysis was performed as previously
described (29,30).
2.5. Time-dependent effect of NHS
E. coli strain JJ1886 from DMSO stock was inoculated
into LB broth and incubated for 24 h at 37 °C. The
concentration of 24-h bacterial culture was adjusted in
PBS to the 0.5 McFarland standard (1.5 × 108 CFU/mL).
The final bacterial concentration was diluted to 5 × 106
CFU/mL. Next, LB broth, NHS (1:2 v/v), HIS (1:2 v/v),
and E. coli strain JJ1886 were added to the wells of a 96-well
plate. The bacteria were treated with NHS, HIS, and LB by
incubation at 37 °C without shaking. Samples were taken
at time intervals of 0, 1, 2, and 3 h (31). Serial dilution was
performed in a sterile 1X PBS buffer and plated on Luria
agar (LA) plates by drop test, as previously described (32).
The time-dependent effect of serum on bacterial growth
was calculated as log10 CFU/mL after incubation at 37° C
for 24 h (n = 3).
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2.6. Time-dependent effect of NHS and β-lactam
antibiotics
Measurement of the time-dependent effect of NHS and
β-lactam antibiotics including CTX, CAZ, and CAR
was performed as mentioned in Section 2.5. Briefly, the
concentrations of CTX, CAZ, and CAR were diluted in LB
broth in 96-well plates as follows: 512–0.125 µg/mL, 5120–
2.5 µg/mL, and 20–0.625 mg/mL, respectively. After that,
LB broth, NHS (1:2 v/v), HIS (1:2 v/v), and E. coli strain
JJ1886 were added to each well containing CTX, CAZ, or
CAR. Samples were withdrawn at time intervals of 0, 1, 2,
3, and 24 h from the well equal to the MIC value for each
antibiotic. Time-dependent effects of NHS and β-lactam
antibiotics was calculated as log10 CFU/mL after 24 h of
incubation at 37 °C (n = 3).
2.7. Standard PCR
In order to determine the level of expression of serum
resistance and β-lactamase-associated genes in the
presence of β-lactam antibiotics and NHS, the genes
encoding β-lactamase (blaCTX-M), β-lactamase regulator
(ampE), lipoprotein NlpI (nlpI), murein lipoprotein (lpp),
lipopolysaccharide core heptose (I) kinase (rfaP), LPS
biosynthesis protein (wbbJ), capsule biosynthesis (kpsS),
peptidoglycan glycosyltransferase (ftsI), and phosphate
transport system regulator (phoU) were confirmed by
standard PCR as follows: isolation and purification
of bacterial genomic DNA were performed using the
GeneALL Genomic DNA Purification Kit (Korea). PCR
was carried out in a final volume of 25 µL containing 1.25
U of Taq DNA polymerase (Thermo Fisher Scientific)
in 1X PCR buffer, 0.2 µM of each dNTP, 2 mM MgCl2,
and 1 µM of each primer (Table 1). The program of PCR
included initial denaturation at 95 °C for 2 min, followed
by 30 cycles of 95° C for 5 s and 55.5 °C for 1 min, with a
final extension step at 72 °C for 2 min. The amplicon size
was determined by 1.0% agarose gel electrophoresis (Table
1). The primers for each gene were designed according
to the genome-sequenced E. coli strain JJ1886 (NCBI
Reference Sequence: NC_022648; the reference sequence
was derived from CP006784).
2.8. Total RNA isolation and cDNA synthesis
For the examination of the expression of serum resistance
and β-lactamase-associated genes, total RNA isolation of
E. coli strain JJ1886 was performed using the Hybrid-R
Total RNA Isolation Kit (Korea). Briefly, the concentration
of 24-h bacterial culture was adjusted to OD600 of 0.05 with
fresh LB medium. Next, bacterial culture was immediately
added to the LB medium (control) and LB medium
consisting of NHS (v/v 1:2), HIS (v/v 1:2) NHS + CTX, NHS
+ CAZ, NHS + CAR, HIS + CTX, HIS + CAZ, HIS + CAR,
CTX, CAZ, and CAR. Final antibiotic concentrations were
calculated according to the MIC values and incubated at 37
°C for 24 h with shaking (50 rpm). The bacterial cultures
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(24 h) of 12 different conditions were used for total RNA
isolation. Isolated mRNA was stored at –80 °C until cDNA
synthesis analysis.
cDNA synthesis analysis was carried out, followed
by RNA isolation from each condition (LB medium control; LB medium consisting of NHS [v/v 1:2], HIS
[v/v 1:2], NHS + CTX, NHS + CAZ, NHS + CAR, HIS
+ CTX, HIS + CAZ, HIS + CAR, CTX, CAZ, and CAR).
cDNA synthesis was performed using a Biospeedy cDNA
synthesis kit (Turkey) as follows: 12 µL of mRNA was
mixed with 4 µL of oligo-dT and incubated for 10 min at
70 °C. cDNA synthesis was carried out in a final volume of
40 µL including 8 µL of 5X reaction buffer, 2 µL of dNTP
mix, 2 µL of reverse transcriptase, and 12 µL of RNAse and
nuclease-free water. The reaction mixture was incubated at
37 °C for 60 min. The obtained cDNA was stored at –20 °C.
2.9. Quantitative reverse transcription PCR
Quantitative reverse transcription PCR (RT-qPCR)
was performed using CFX Connect Real-Time PCR
equipment (USA). A final volume of 10 µL of reaction
mixture consisted of 1.5 mM MgCl2, 0.2 mM dNTP mix,
1X reaction buffer, 1 U Fast Start Taq DNA polymerase,
0.1X EvaGreen, 4 ng/µL cDNA, and 0.5 µM of each primer.
The annealing temperature for each gene ranged from 55
to 57.5 °C. The qPCR program included preincubation (95
°C for 10 min), followed by 40 cycles of amplification (95
°C for 15 min, 55–57.5 °C for 20 s, 72 °C for 40 s) and
melting curve (95 °C for 2 s and 65 °C for 1 min). The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene was used for normalization of the expression of target
genes, including CTX-M-15, ampE, ftsI, nlpI, lpp, rfaP,
wbbJ, kpsS, and phoU (Table 1).
2.10. Statistics
The GraphPad Prism 5.0 (San Diego, CA, USA) program
was used for all statistical analyses. Two-way ANOVA was
carried out. Bonferroni posttests were applied. P-values of
less than 0.0001 were considered significant.
3. Results
E. coli strain JJ1886 was determined to be a β-lactam
producer using the nitrocefin phenotypic test. By MIC
testing, E. coli strain JJ1886 was shown to be resistant to
CTX, CAZ, and CAR, with MICs of 1280 µg/mL, 16 µg/
mL, and 20 mg/mL, respectively. Because E. coli strain
JJ1886 was resistant to CAR concentrations between
512 and 0.125 µg/mL, the MIC was detected at a higher
concentration (20 mg/mL) for this antibiotic.
During the analysis of the time-dependent effect of
NHS on the growth of E. coli strain JJ1886 during the
exponential growth phase, the bacterium was treated with
serum at 37 °C. We found that the growth rate decreased
between the 0-h and 1-h time intervals. However, the
bacterial cell number increased after 2 h of treatment
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Table 1. Primers used in this study.
Gene

Sequence (5′→3′)

Locus_Tag

Size (bp)

Description

Reference

ATGTGCAGYACCAGTAARGT

NA

593

Internal region of the
blaCTX-M genes

(42)

P423_RS00600

734

Beta-lactamase regulator
AmpE

This study

P423_RS18500

758

Lipoprotein NlpI

This study

P423_RS09290

188

Murein lipoprotein

This study

P423_RS20930

606

Lipopolysaccharide core
heptose (I) kinase RfaP

This study

P423_RS12005

556

LPS Biosynthesis protein
WbbJ; catalyzes the transfer
This study
of the O-acetyl moiety to the
O antigen

P423_RS00470

821

Peptidoglycan
glycosyltransferase FtsI,
penicillin-binding protein 3

This study

P423_RS21470

546

Phosphate transport system
regulator PhoU

This study

P423_07345

174

Class A extended-spectrum
beta-lactamase CTX-M-15

This study

P423_RS00600

248

Beta-lactamase regulator
AmpE

This study

P423_RS18500

172

Lipoprotein NlpI

This study

P423_RS09290

179

Murein lipoprotein (Lpp)

This study

P423_RS20930

229

Lipopolysaccharide core
heptose (I) kinase

This study

P423_RS12005

231

LPS biosynthesis protein

This study

Standard PCR
blaCTX-M

TGGGTRAARTARGTSACCAGA
ampE

GTGTTAATTTTCGAGCGCCT
ACCTTATCGACATGCGGTTC

nlpI

TTGCTGGTCCGATTCTGC
TGATTCTGGCACGTATGGAA

lpp

GCGGTAATCCTGGGTTCTACT
ATGTTGTCCAGACGCTGGTT

rfaP

ATGCTCGGCCTTAACACTTG
GGCACGACCCTGAAAGAG

wbbJ

TCCCATTGCATACGCTCATA
GCCTTTATGGTGGTCTTAGGC

ftsI

CATGGCGGACTACATCAAAA
CGTAGCCGAAAGAGAAGGTG

phoU

AGTACGCTCGGAATGGTACG
ACATATTTCCGGCCAGTTCA

qPCR
CTX-M-15

GCTGAAGAAAAGTGAAAGCGA
AGCTTATTCATCGCCACGTT

ampE

GCAGGTAAAGTTCGTCTTCATTATC
GCATACCCCATCAGCGTAAC

nlpI

ACGTTTGTTCGCTAATGTTGC
CAAGACGATCCCAATGATCC

lpp

GCGGTAATCCTGGGTTCTACT
AGACGCTGGTTAGCACGAG

rfaP

CAAATCTTTATCCCGCCAAC
GACCAACCCACCAGATGTTC

wbbJ

TCCACACACGCTCTCCAATA
TGGATGCCGTAGTTTCCATT
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Table 1. (Continued).

ftsI

GTCGATAGCCAAGGGATTGA

P423_RS00470

216

Peptidoglycan
glycosyltransferase FtsI;
penicillin-binding protein 3

This study

P423_RS17345

219

Polysialic acid capsule
synthesis protein (KpsS)

This study

P423_RS21470

210

Phosphate transport system
regulator (PhoU)

This study

P423_RS08270

249

Type I glyceraldehyde
3-phosphate dehydrogenase

This study

GTTAAAGGCCACTGCGTTGT
kpsS

TACCGTTGAAGAAGGCGG
TCATACCAGGGGGAAAATGA

phoU

GTACCGCTTCGTCAATGTCC
TGCGTCTGGTGATGGTAATC

GAPDH

TTTTTCCGAGAATCGACACC
GGATAGAAGTCGGCACGATG

with NHS, likely due to its resistance to NHS (Figure
1A). For the quality control strain (E. coli ATCC 25922),
a rapid decrease in cell number was reported in the first
hour of the treatment with NHS (Figure 1B). In addition,
we found that HIS-treated E. coli strain JJ1886 and E. coli
ATCC 25922 showed a significant increase in cell numbers
(7–8 log10 CFU/mL) after 2 h of treatment at 37 °C.
E. coli strain JJ1886 was treated with NHS or HIS plus
CTX (1280 µg/mL), CAZ (16 µg/mL), and CAR (20 mg/
mL). During the treatment with CAZ (16 µg/mL), in the
exponential growth phase, E. coli strain JJ1886 showed
resistance to NHS in the first hour. However, compared with
HIS + CAZ in LB medium, the number of cells decreased
after 2 h. During the 3- to 24-h time interval, NHS + CAZ
showed bactericidal activity against E. coli strain JJ1886.
There was a decrease in cell count after 3 h when HIS and
CAZ were present in growth media. However, when only
CAZ was present, bacterial growth was inhibited until the
third hour of treatment with the serum, but the number
of cells doubled after 24 h of culturing compared to the
beginning of treatment (0 h) (Figure 2).
Similar results were obtained with CTX when E. coli
strain JJ1886 was treated with 1280 µg/mL CTX, NHS,
and HIS. However, it was observed that the number of
cells decreased after 3 h of treatment with NHS + CTX. We
found that NHS + CTX had a bactericidal effect at 24 h.
When both HIS and CTX were in the growth medium, the
cell number did not change until the 3-h time point, but
the cell number increased swiftly at 24 h. However, when
only CTX was present in the medium, bacterial growth
was inhibited until the third hour of treatment, but cell
number increased at 24 h (Figure 3).
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Figure 1. Time-dependent effect of NHS and HIS on bacterial
growth. E. coli strain JJ1886 was incubated with NHS, HIS, and
LB. Log10 CFU/mL was calculated at specified time intervals.
JJ1886_NA: E. coli strain JJ1886 without antibiotics (A). E.
coli ATCC 25922 quality control strain was incubated with
NHS, HIS, and LB. Log10 CFU/mL was calculated at specified
time intervals. ATCC_NA: E. coli ATCC 25922 strain without
antibiotics (B). Mean and standard deviations were calculated
from at least three independent experiments.
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(16μ g/mL)

Figure 2. Time-dependent effect of NHS and HIS together
with ceftazidime on bacterial growth. E. coli strain JJ1886 was
incubated with NHS, HIS, and LB together with ceftazidime at
37 °C. The sample was withdrawn from the well corresponding
to the MIC value. Log10 CFU/mL was calculated at specified time
intervals. Mean and standard deviations were calculated from at
least three independent experiments. ***: P < 0.0001.

(1280μ g/mL)

resistance at the second hour and the cell number increased
at 24 h (Figure 4).
The quantitative expression of serum resistance and
β-lactam-associated genes of E. coli strain JJ1886 was
investigated by treatment with CAZ, CTX, CAR, NHS, and
HIS (LB as a control; NHS, HIS, NHS + CTX, NHS + CAZ,
NHS + CAR, HIS + CTX, HIS + CAZ, HIS + CAR, CTX,
CAZ, and CAR). Serum resistance and β-lactamase-related
genes are shown in Table 1. All relative gene expression was
evaluated for downregulation or upregulation according
to the control value of 1. A minimum 0.5-fold change was
used as the cut-off for downregulation and a minimum
2-fold relative increase for upregulation (Table 2; Figure 5).
There was no significant relative gene expression change
for CTX-M-15, ampE, ftsI, nlpI, lpp, rfaP, wbbJ, kpsS, or
phoU. Thus, the coexistence of serum and antibiotics in the
growth medium did not alter the relative expression of the
indicated genes. However, a significant downregulation
was observed for the nlpI gene following treatment with
CAR (Figure 5; Table 2).
4. Discussion
Certain E. coli strains present in the bloodstream may
lead to serious infections, such as sepsis and urinary tract
infections. Surviving in the bloodstream and overcoming
host defense mechanisms are necessary virulence traits
for E. coli. These virulence traits involve iron acquisition
systems and serum resistance-associated factors (23).
Previous studies have shown that serum survival factors
allow pathogenic bacteria to survive in serum. These factors

(20 mg/mL)

Figure 3. Time-dependent effect of NHS and HIS together
with cefotaxime on bacterial growth. E. coli strain JJ1886 was
incubated with NHS, HIS, and LB together with cefotaxime at
37 °C. The sample was withdrawn from the well corresponding
to the MIC value. Log10 CFU/mL was calculated at specified time
intervals. Mean and standard deviations were calculated from at
least three independent experiments.

A decrease in cell number was observed after 1 h of
treatment of E. coli strain JJ1886 with 20 mg/mL CAR,
NHS, and HIS. However, when NHS and CAR were used
together in the growth medium, E. coli O25b:H4 showed

Figure 4. Time-dependent effect of NHS and HIS together
with carbenicillin on bacterial growth. E. coli strain JJ1886 was
incubated with NHS, HIS, and LB together with carbenicillin at
37 °C. Sample was withdrawn from the well corresponding to
the MIC value. Log10 CFU/mL was calculated at specified time
intervals. Mean and standard deviations was calculated from at
least three independent experiments. ***: P < 0.0001.
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Table 2. Fold change values of CTX-M-15, nlpI, ampE, lpp, rfaP, wbbJ, ftsI, kpsS, and phoU genes.
Control and
NHS
genes

HIS

CTX

CAZ

CAR

NHS +
CTX

NHS +
CAZ

NHS +
CAR

HIS +
CTX

HIS +
CAZ

HIS +
CAR

CTX-M-15
Fold change

1.00

0.91

1

0.72

1.27

1.37

1.08

1.18

1.02

0.73

0.8

0.53

St. dev.

0.00

0.16

0.17

0.37

0.05

0.03

0.1

0.53

0.07

0.05

0.1

0.35

nlpI
Fold change

1.00

1.05

0.82

0.87

0.58

0.43

1.03

1.12

0.99

0.92

0.96

1.71

St. dev.

0.00

0.27

0.57

0.07

0.7

0.12

0.14

0.1

0.13

0.18

0.11

0.19

ampE
Fold change

1.00

0.99

1.08

0.92

1.18

1.14

1.21

1.48

1.1

0.93

1.09

1.26

St. dev.

0.00

0.2

0.2

0.06

0.04

0.07

0.09

0.08

0.05

0.07

0.14

0.23

lpp
Fold change

1.00

0.98

1.14

0.92

1.02

1.12

1.03

1.11

0.84

0.88

0.96

0.93

St. dev.

0.00

0.11

0.12

0.11

0.09

0.10

0.06

0.12

0.11

0.08

0.06

0.09

rfaP
Fold change

1.00

1.18

1.37

0.82

0.86

0.91

1.19

0.87

0.93

0.75

0.87

0.92

St. dev.

0.00

0.20

0.19

0.03

0.09

0.08

0.10

0.08

0.37

0.39

0.22

0.55

wbbJ
Fold change

1.00

1.22

1.37

0.84

0.97

0.83

1.5

1.25

0.61

0.64

0.61

0.9

St. dev.

0.00

0.16

0.21

0.08

0.09

0.16

0.05

0.06

0.12

0.13

0.11

0.24

ftsI
Fold change

1.00

1.2

1.21

0.86

1.11

1

1.01

1.33

0.96

0.84

0.95

1.06

St. dev.

0.00

0.16

0.4

0.07

0.02

0.2

0.13

0.04

0.08

0.27

0.35

0.18

kpsS
Fold change

1.00

1.18

1.42

0.78

1.14

1.15

1.47

1.41

1.20

1.00

0.97

1.30

St. dev.

0.00

0.12

0.18

0.37

0.12

0.06

0.16

0.03

0.10

0.13

0.12

0.23

phoU
Fold change

1.00

1.08

1.31

0.90

1.27

1.19

1.48

1.69

1.32

1.23

1.04

1.31

St. dev.

0.00

0.18

0.23

0.10

0.08

0.07

0.09

0.06

0.09

0.11

0.34

0.10

include outer membrane proteins, capsule, O-antigens
of the LPS, periplasmic protease, murein lipoprotein,
and the phosphate transport system (21,24,26,33). Many
pathogenic E. coli pathotypes are known to be serumresistant, including CFTO73, RS218, 536, CP9, and EC958
(23). Among these, EC958 is a O25b:H4-ST131 strain
disseminated globally and a known producer of the CTXM-15-type ESBL (34). Similarly, the E. coli strain JJ1886
is an epidemic clone (O25b:H4-ST131) that is resistant to
numerous β-lactams, including cephalosporins (20). In
this study, we report that E. coli strain JJ1886 is resistant
to serum and β-lactams, including CAZ, CTX, and
CAR. However, CAZ and CTX together with NHS had
bactericidal activity against E. coli strain JJ1886 at the
tested time points.
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A previous investigation reported that the E. coli
CFTO73 strain survived when treated with serum during
the first hour of culture. However, cell number decreased
after the first hour of NHS treatment. These findings show
that the E. coli CFTO73 strain can tolerate serum during
the lag phase of growth (28). In our study, we investigated
the time-dependent effect of NHS on growth E. coli strain
JJ1886 in the exponential growth phase when treated with
NHS at 37 °C. We found that the cell number decreased
between the 0- and 1-h intervals. However, the cell number
increased after 2 h of treatment. It can be speculated that
the susceptibility and tolerance of different E. coli strains
vary when E. coli strains are treated with NHS.
CAZ is a broad-spectrum cephalosporin used against
gram-negative bacteria (35). In our study, only CAZ (16
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Figure 5. Relative expression of nlpI gene. Cultures of E. coli strain JJ1886 after 24 h with 12 different
conditions—control, NHS, HIS, CTX, CAZ, CAR, NHS + CTX, NHS + CAZ, NHS + CAR, HIS + CTX,
HIS + CAZ, and HIS + CAR—were used for RT-qPCR analysis. Final antibiotic concentrations were
calculated according to MIC values. Mean and standard deviations were calculated from at least three
independent experiments. Fold change: Relative mRNA expression, nlpI: a gene encoding lipoprotein
NlpI.

µg/mL) in the LB medium showed an inhibitory effect
on E. coli JJ1886 cells within the first 3 h. However,
the number of cells increased at the 24-h time point
(Figure 3). Similarly, Keepers et al. reported regrowth of
Enterobacteriaceae when treated with CAZ and avibactam
during 24-h measurement of bactericidal activity (35).
Similar results were obtained for CTX (1280 µg/mL)
and CAR (20 mg/mL) in this study. More precisely, CTX
and CAR had an inhibitory effect until 3 h of culturing.
However, the cell number almost doubled at 24 h after
treatment. A previous study stated that the death rate of
bacteria treated with β-lactam antibiotics was comparable
to the growth rate (36). In other words, β-lactam antibiotics
inhibit the formation of peptidoglycan synthesis during
bacterial growth and cause cell lysis, thus affecting the
growth rate and tolerance of the bacterium. Therefore,
the inhibitory effect of β-lactam antibiotics can be timedependent for E. coli strain JJ1886 cells until a certain
time interval. Afterwards, E. coli strain JJ1886 cells
proliferated during the 24-h treatment with CAZ, CTX,
and CAR. Thus, it can be concluded that E. coli JJ1886
cells could tolerate the inhibitory effect of CAZ, CTX, and
CAR when exposed to β-lactam antibiotics over a longer
period. Another reason why E. coli JJ1886 cells regrew at
the end of the 24-h culture period is the inoculum effect
of β-lactamase-producing strains when compared to nonβ-lactamase-producing strains (37). It has been suggested

that the starting inoculum (1 × 106 to 5 × 106 CFU/mL)
could lead to regrowth of bacteria.
When E. coli JJ1886 cells were incubated with β-lactam
antibiotics (CAZ and CTX) together with serum, the
cell number decreased, and eventually a bactericidal
effect of NHS and β-lactam antibiotics (CAZ and CTX)
was detected (Figures 2 and 3). However, when NHS
and CAR were added together to growth media, cell
number increased at the 3- and 24-h time points (Figure
4). A previous investigation of the bactericidal effect
of antibiotics in human serum demonstrated that the
complement-mediated effect makes bacterial cells more
susceptible to antibiotics (38). However, here we found
that, even though CAR + NHS were present in growth
media, E. coli strain JJ1886 was resistant (Figure 4). Based
on this finding, it can be inferred that E. coli strain JJ1886
is tolerant to both CAR and NHS.
We investigated the relative gene expression of serum
resistance and β-lactamase-associated genes in the
presence of NHS, HIS, CAZ, CTX, and CAR. A significant
downregulation was observed for the nlpI gene, which
encodes lipoprotein NlpI, when E. coli strain JJ1886 was
treated with CAR only (Figure 5; Table 2). Lipoprotein NlpI
is an outer membrane lipoprotein involved in cell division.
It has been reported that NlpI together with periplasmic
protease (Prc) controls peptidoglycan synthesis by
changing levels of MepS, which is an endopeptidase
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that breaks the peptide crosslink of the peptidoglycan
component. In other words, NlpI binds to the Prc and
MepS in order to degrade MepS via Prc (39). NlpI also
contributes to the deposition of the complement regulator
C4bp of E. coli in order to escape killing by serum (24). In
addition to being associated with NlpI, Prc (also known
as Tsp) contributes to pathogenicity by improving serum
survival. Moreover, Prc processes the carboxy C-terminal
region of the periplasmic protein and penicillin-binding
protein 3, which is responsible for mediating peptidoglycan
synthesis (33). In our study, growth analysis showed
that E. coli strain JJ1886 was resistant to CAR and NHS
during the 24-h incubation, and the nlpI gene encoding
lipoprotein NlpI was downregulated in the presence of
CAR. CAR is a carboxypenicillin, and E. coli strains that
have surface β-lactamase are resistant to CAR (40). The
mode of action of CAR is to inhibit cell wall synthesis
during peptidoglycan cross-linking; this could affect the
cell wall and periplasm membrane (41). Downregulation
of the nlpI gene might be related to the peptidoglycan
biosynthesis process. However, the exact reason why a

downregulation was observed in the nlpI gene is unclear.
To develop a more accurate conclusion requires further
studies on the nlpI gene in E. coli strain JJ1886.
Taken together, our data show that during the
exponential growth phase, E. coli strain JJ1886 is resistant
to NHS. When the bacterium was treated with NHS
together with β-lactam antibiotics, including CAZ and
CTX, we detected a bactericidal effect. However, E. coli
strain JJ1886 cells were resistant to NHS in combination
with CAR. Our findings may show that these cells can
tolerate the inhibitory effect of CAR and NHS. Moreover,
there was no significant change in gene expression for
encoding class A extended-spectrum beta-lactamase
CTX-M-15, β-lactamase regulator, penicillin-binding
protein 3, and serum survival-related factors, except for
the nlpI gene encoding lipoprotein NlpI.
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